NewAmsterdam Pharma Company N.V. (NAMS) NASDAQ

27.00

+1.34(+5.22%)

Updated at September 05 04:00PM

Currency In USD

NewAmsterdam Pharma Company N.V.

Address

Gooimeer 2-35

Naarden, 1411 DC

Netherlands

Phone

31 35 206 2971

Sector

Healthcare

Industry

Biotechnology

Employees

68

First IPO Date

February 09, 2021

Key Executives

NameTitlePayYear Born
Dr. Michael Harvey Davidson FACC, Facp., M.D.Chief Executive Officer, President, Executive Board Member & Director1.12M1956
Ms. Juliette Audet M.B.A., M.Sc.Chief Strategy & Business Officer653,0391987
Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.Founder, Chief Scientific Officer, Member of Executive Board & Director813,0771954
Mr. Mayur Amrat SomaiyaChief Financial Officer841,2381974
Mr. Douglas F. KlingChief Operating Officer913,7421973
Mr. Matthew PhilippeExecutive Vice President &Head of Investor Relations0N/A
Ms. Louise KooijChief Accounting Officer01976
Dr. Marc Ditmarsch M.D.Chief Development Officer01967
Ms. Maryellen McQuadeChief People Officer0N/A
Mr. Bob RamboExecutive Vice President of Marketing0N/A

Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.